Findings

What do systematic reviews say?

61 questions · 65 findings · 28 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 40 · 61.5%GRADE not reported 4 · 6.2%Very low 5 · 7.7%Low 7 · 10.8%Moderate 6 · 9.2%High 3 · 4.6%

Macrolides vs placebo

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Azithromycin vs placebo or usual care

Quality of life at longest · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Azithromycin vs placebo or usual care

Quality of life at longest · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Macrolides vs placebo

Quality of life not reported · children with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

28 days on/off antibiotic regimen vs 28 days on/off placebo regimen

Health‐related quality of life · people with bronchiectasis

2 findings from 1 review

Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate
Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

14 days on/off antibiotic regimen vs 28 days on/off antibiotic regimen

Health‐related quality of life · people with bronchiectasis

2 findings from 1 review

Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High
Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

14 days on/off antibiotic regimen vs 14 days on/off placebo regimen

Health‐related quality of life · people with bronchiectasis

2 findings from 1 review

Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High
Intermittent prophylactic antibiotics for bronchiectasis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Topical quinolone vs intramuscular gentamicin

Health‐related quality of life · adults with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical quinolone vs oral amoxicillin‐clavulanic acid combination

Health‐related quality of life · adults with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical quinolone vs quinolones

Health‐related quality of life · people (of any age) with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · CSOM, recurrence of CSOM or suppuration following mastoidectomy or tympanoplasty

The review found no eligible studies for this question.

1 finding from 1 review

Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quinolone vs aminoglycosides

Health‐related quality of life · people (of any age) with CSOM

The review found no eligible studies for this question.

1 finding from 1 review

Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs no intervention

Quality of life ‐ not reported · children with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral azithromycin vs placebo

QoL · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 177 participants
Moderate

Linezolid vs vancomycin

Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cefepime vs ceftazidime

Health‐related quality of life Maximum · neonates and children with hospital‐acquired pneumonia

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Quality of life: change from baseline in CFQ‐R · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
Low

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 294 participants
Moderate

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Quality of life: respiratory domain · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low